Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02673749
Other study ID # G28-003
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received January 25, 2016
Last updated April 2, 2018
Start date February 2016
Est. completion date October 2016

Study information

Verified date April 2017
Source Ritter Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).


Description:

Lactose intolerance is a common gastrointestinal (GI) disorder that develops in lactose maldigesters when consuming lactose or when lactose is added to a previously low-lactose diet. Lactose intolerance is characterized by one or more of the cardinal symptoms that follow the ingestion of lactose-containing foods. These symptoms include; abdominal pain, cramping, bloating, flatulence [gas] and diarrhea. As such, most lactose intolerant individuals avoid the ingestion of milk and dairy products, while others substitute non-lactose containing products in their diet. Currently, there are no approved treatments for this condition.

Based on the health implications from insufficient calcium intake over a lifetime, including increased risk of osteoporosis and hypertension, there is need in the medical community for a tolerable and convenient treatment that allows for all levels of milk and dairy product consumption in people suffering from mild to severe lactose intolerance.

Study Objective:

To access efficacy of two RP-G28 dosing regimes on symptoms related to lactose intolerance relative to placebo after 30 days of treatment. The 30 day post-treatment phase will further evaluate the treatment's potential to prolong relief from symptoms.

Study Design:

The participants will take about 60 days to complete the study. The study consists of 3 distinct phases: Screening, a 30-day Treatment Phase, and a 30-day Post-Treatment Phase (off study treatment observation period). A participant will need to visit the clinical only 6 times throughout the study.


Recruitment information / eligibility

Status Completed
Enrollment 377
Est. completion date October 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion/Exclusion Criteria:

- Female subjects must be non pregnant, and non lactating. Females of childbearing potential must use adequate birth control during study participation

- Medical history of intolerance to milk and other dairy products, and/or confirmed physician diagnosis of lactose intolerance.

- Must be free from any disorder known to be associated with gastrointestinal disease: irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), Celiac disease, diverticulitis, chronic constipation, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, small intestine bacterial overgrowth syndrome (SIBO), active gastric or duodenal ulcers, or history of severe ulcers.

- Must be nicotine free.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RP-G28
Study drug taken orally
Other:
Placebo
Placebo taken orally

Locations

Country Name City State
United States Covance, Inc. Princeton New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Ritter Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in abdominal pain Percent change from baseline to Day 31 of AUC abdominal pain symptom score based on measures taken after a lactose challenge test at 1, 2, 3, 4, and 5 hours. The method of assessment for this outcome measure is an 11-point numeric rating scale completed by the subject. Day 31
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Completed NCT02518295 - β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion N/A
Completed NCT00599859 - Effects of Lactose on Fecal Microflora N/A
Completed NCT02636413 - Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance Phase 4
Completed NCT02406469 - Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior Phase 4
Terminated NCT00247806 - Prevalence of Lactose Intolerance Following Stem Cell Transplantation Phase 1
Completed NCT03814668 - Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Lactose Solution N/A
Completed NCT03860051 - Association Between Lactase Deficiency, and the Small Intestinal Microbiome in Adults.
Not yet recruiting NCT06107088 - Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance N/A
Completed NCT02703987 - HYBRID: Hydrogen Breath Test in Lactose Digestion N/A
Completed NCT00395954 - Amount of Lactose Causing Symptoms in Lactose Intolerant People Phase 0
Completed NCT01593800 - The Effect of Probiotics on Lactose Intolerance N/A
Completed NCT04164394 - Effect of I31 Probiotic on Lactose Intolerance N/A
Recruiting NCT05668468 - A Bifido Bacteria to Improve Lactose Digestion and Tolerance N/A
Completed NCT03563846 - Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects Phase 1
Recruiting NCT02085889 - Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
Completed NCT03597516 - Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance Phase 3
Not yet recruiting NCT03563859 - Evaluation of Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance Phase 3
Completed NCT02171403 - Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls N/A
Completed NCT01145586 - A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia Phase 3